Competitive Rivalry

ARE competes with large, well-capitalized life-science landlords, but specialized lab campuses and long lease terms reduce direct price competition versus more commoditized office REITs.

High tenant switching costs and build-to-suit fit-outs support rent retention, yet peer portfolios in Boston, San Diego, and the Bay Area still compete for the same R&D demand.

Supply additions in core clusters can pressure renewal spreads and occupancy, but ARE’s scale and portfolio concentration make rivalry more manageable than for smaller niche peers.

Peer pricing remains disciplined in top innovation hubs, but weaker demand periods can still compress concessions and slow mark-to-market growth across the sector.

Threat Of New Entrants

High land costs, zoning constraints, and specialized permitting in life-science clusters create meaningful barriers that limit new supply versus generic commercial real estate.

Lab-ready development requires technical expertise, long lead times, and tenant preleasing, which raises capital intensity and deters smaller entrants relative to ARE’s established peers.

Institutional capital can still enter the sector, but the combination of scale, entitlements, and tenant relationships makes it harder to replicate ARE’s portfolio footprint quickly.

New supply is most likely from existing developers rather than true entrants, so structural barriers remain stronger than in most property subsectors.

Bargaining Power Of Suppliers

Construction labor, specialized MEP contractors, and life-science build-out vendors can command premium pricing, which raises development costs versus standard office assets.

In tight labor markets, supplier inflation can compress development yields for ARE and peers, although long-duration projects allow some cost pass-through in preleased deals.

Land sellers in core clusters hold leverage because scarce entitled sites are difficult to replace, but this constraint affects the whole peer set similarly.

ARE’s scale helps source contractors and materials, yet supplier power remains structurally meaningful because lab specifications limit substitution and standardization.

Bargaining Power Of Buyers

Large pharmaceutical and biotech tenants negotiate aggressively on rent, TI allowances, and free rent, especially when they can compare multiple lab campuses across top markets.

Tenant concentration in a few large occupiers increases renewal sensitivity, which can pressure spreads when demand softens or funding conditions tighten.

However, mission-critical lab space and relocation costs reduce buyer flexibility versus office tenants, limiting the extent of rent compression.

Peer landlords face similar tenant sophistication, so buyer power is material but not uniquely punitive for ARE relative to global life-science REITs.

Threat Of Substitutes

For some tenants, hybrid work and outsourced R&D can reduce space needs, but wet-lab requirements make true substitutes far less available than in office real estate.

Purpose-built lab space remains difficult to replace with generic industrial or office assets, preserving ARE’s pricing power versus broader commercial property peers.

Public cloud, CROs, and shared innovation facilities can substitute for certain research functions, yet they do not fully replace core in-house laboratory demand.

Because substitutes are partial rather than direct, they constrain growth more than they compress rents, leaving ARE better insulated than most property owners.

Overall Score

ARE benefits from high structural barriers to entry and limited substitutes, but competitive tenant bargaining and specialized supplier costs keep overall industry economics only moderately favorable versus global peers.